Capstone Energy+ Eyes Data Centers With ‘Energy Certainty’ Push

Capstone Energy Plus, Inc. (CEPL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Capstone Energy+ Reports Results for First Quarter of Fiscal 2027 Gross Profit Increased 16% to $8.8 Million ​ Company Generated $5.4 Million in Operating Cash Flow ​ LOS ANGELES, CA / BUSINESS WIRE / August 12, 2026 — Capstone Energy+, Inc. (NASDAQ: CEPL) (“Capstone

BioNTech (BNTX) and Bristol Myers Squibb (BMY) reported Phase 2 trial data for pumitamig plus docetaxel in metastatic non-small cell lung cancer. The trial showed a 36.7% objective response rate and 90.0% disease control rate. Median progression-free survival was 6.9 months. Adverse events were reported in 52.0% of patients, with 18.0% grade 3 or higher. Data were presented at the European Society for Medical Oncology Congress 2026.

Eli Lilly presented data at ESMO 2026 showing promising results for olomorasib, an investigational treatment for KRAS G12C-mutant non-small cell lung cancer (NSCLC). The data showed durable efficacy in combination with immunotherapy, with or without chemotherapy, across PD-L1 expression levels. Olomorasib is not yet approved but has received Breakthrough Therapy designation from the FDA. The ongoing Phase 3 SUNRAY-01 study is evaluating olomorasib in first-line KRAS G12C-mutant NSCLC.

BioNTech (BNTX) and Bristol Myers Squibb (BMY) reported Phase 2 trial data for pumitamig plus docetaxel in advanced NSCLC. The combination showed a 36.7% objective response rate and 6.9-month median progression-free survival. The trial involved 50 patients, with responses observed across PD-L1 levels and histologies. The companies are advancing pumitamig in multiple lung cancer trials.

Innovent Biologics (HKEX: 01801) presented Phase 1 data for IBI3001, a first-in-class EGFR/B7H3 bispecific ADC, at the 2026 ESMO Congress. The study showed manageable safety and encouraging efficacy across multiple solid tumors, including NSCLC, pancreatic cancer, and SCLC. The overall ORR was 30.2%, and the DCR was 88.7%. IBI3001 is advancing to Phase 1b dose-optimization studies.

Amgen's Imdelltra combined with AstraZeneca's Imfinzi showed a 58% reduction in death risk for extensive-stage small cell lung cancer patients, increasing median survival to 21.1 months. The study, presented at the European Society for Medical Oncology Congress, suggests potential for Imdelltra as a first-line maintenance therapy. Imdelltra reported $288M in Q2 2023 sales and $627M in 2025 global sales.